Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Horwich

Showing results (51-60 of 84) with videos related to

Pageof 9
Sort By:
European Urology|August 23, 2015
Guidelines on Testicular Cancer: 2015 UpdatePeter Albers, Walter Albrecht, Ferran Algaba, et al.
European Urology|April 3, 2012
The contemporary role of chemotherapy for advanced testis cancer: a systematic review of the literatureFabio Calabrò, Peter Albers, Carsten Bokemeyer, et al.
European Urology|March 12, 2013
Medium-term outcomes of active surveillance for localised prostate cancerElizabeth D Selvadurai, Mausam Singhera, Karen Thomas, et al.
Annals of Hematology|October 26, 2013
GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphomaEliza A Hawkes, Sarah Barton, David Cunningham, et al.
BJU International|November 8, 2008
Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling timeMichael K Ng, Nicholas Van As, Karen Thomas, et al.
European Urology|March 18, 2008
Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillanceNicholas J van As, Andrew R Norman, Karen Thomas, et al.
International Journal of Radiation Oncology, Biology, Physics|January 23, 2010
Expression of Bcl-2, p53, and MDM2 in localized prostate cancer with respect to the outcome of radical radiotherapy dose escalationRoy Vergis, Catherine M Corbishley, Karen Thomas, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 11, 2010
The diagnostic utility of the flare phenomenon on bone scintigraphy in staging prostate cancerGary J R Cook, Ram Venkitaraman, Aslam S Sohaib, et al.
European Journal of Haematology|July 22, 2014
Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R-GEM-P) is an effective regimen in relapsed diffuse large B-cell lymphomaSarah Barton, Eliza A Hawkes, David Cunningham, et al.
Leukemia & Lymphoma|December 10, 2016
Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003-2013Mary Gleeson, Eliza A Hawkes, Clare Peckitt, et al.
Pageof 9

Showing results (51-60 of 84) with videos related to

Sort By:
Pageof 9
European Urology|August 23, 2015
Guidelines on Testicular Cancer: 2015 UpdatePeter Albers, Walter Albrecht, Ferran Algaba, et al.
European Urology|April 3, 2012
The contemporary role of chemotherapy for advanced testis cancer: a systematic review of the literatureFabio Calabrò, Peter Albers, Carsten Bokemeyer, et al.
European Urology|March 12, 2013
Medium-term outcomes of active surveillance for localised prostate cancerElizabeth D Selvadurai, Mausam Singhera, Karen Thomas, et al.
Annals of Hematology|October 26, 2013
GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphomaEliza A Hawkes, Sarah Barton, David Cunningham, et al.
BJU International|November 8, 2008
Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling timeMichael K Ng, Nicholas Van As, Karen Thomas, et al.
European Urology|March 18, 2008
Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillanceNicholas J van As, Andrew R Norman, Karen Thomas, et al.
International Journal of Radiation Oncology, Biology, Physics|January 23, 2010
Expression of Bcl-2, p53, and MDM2 in localized prostate cancer with respect to the outcome of radical radiotherapy dose escalationRoy Vergis, Catherine M Corbishley, Karen Thomas, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 11, 2010
The diagnostic utility of the flare phenomenon on bone scintigraphy in staging prostate cancerGary J R Cook, Ram Venkitaraman, Aslam S Sohaib, et al.
European Journal of Haematology|July 22, 2014
Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R-GEM-P) is an effective regimen in relapsed diffuse large B-cell lymphomaSarah Barton, Eliza A Hawkes, David Cunningham, et al.
Leukemia & Lymphoma|December 10, 2016
Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003-2013Mary Gleeson, Eliza A Hawkes, Clare Peckitt, et al.
Pageof 9